EDIT — Editas Medicine Cashflow Statement
0.000.00%
- $128.91m
- -$83.57m
- $32.31m
Annual cashflow statement for Editas Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -116 | -193 | -220 | -153 | -237 |
Depreciation | |||||
Non-Cash Items | 34.4 | 45.1 | 28.6 | 16.6 | 17.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -102 | -21.4 | 8.18 | -1.59 | 3.45 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -180 | -164 | -177 | -132 | -210 |
Capital Expenditures | -7.16 | -7.98 | -4.12 | -4.72 | -8.83 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -133 | -46.5 | 118 | 0.988 | 171 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -141 | -54.5 | 114 | -3.73 | 162 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 224 | 282 | 1.28 | 118 | 56 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -96.2 | 63.8 | -62 | -17.9 | 7.89 |